LeMaitre Vascular, Inc. Stock

$83.69

2.41% day before yesterday

Nasdaq, Jul 11, 10:00 pm CET

ISIN

US5255582018

Symbol

LMAT

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

LeMaitre Vascular, Inc. Stock price

$83.69

+57.52 219.77% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-2.07 2.41%

ISIN

US5255582018

Symbol

LMAT

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$1.9b

Enterprise Value

$1.8b

Net debt

positive

Cash

$302.6m

Shares outstanding

22.6m

Valuation (TTM | estimate)

P/E

42.3 | 38.1

P/S

8.4 | 7.6

EV/Sales

7.8 | 7.0

EV/FCF

42.7

P/B

5.4

Dividends

DPS

$0.64

Yield 1Y | 5Y

0.8% | 1.0%

Growth 1Y | 5Y

14.3% | 13.5%

Payout 1Y | 3Y

33.2% | 40.5%

Increased

14 Years

Financials (TTM | estimate)

Revenue

$226.3m | $250.4m

EBITDA

$58.7m | $74.1m

EBIT

$53.0m | $59.3m

Net Income

$45.2m | $49.6m

Free Cash Flow

$41.1m

Growth (TTM | estimate)

Revenue

13.2% | 13.9%

EBITDA

25.2% | 27.8%

EBIT

29.6% | 13.5%

Net Income

33.0% | 12.7%

Free Cash Flow

24.5%

Financial Health

Equity Ratio

61.1%

Return on Equity

13.1%

ROCE

10.0%

ROIC

16.5%

Debt/Equity

0.5

EPS

$2.0

FCF per Share

$1.8

Short interest

7.8%

Employees

658

Rev per Employee

$330.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

LeMaitre Vascular, Inc. Stock Analysis

Unlock Scores for Free

??

17 Analysts have issued a LeMaitre Vascular, Inc. forecast:

10x Buy

59%

7x Hold

41%

More details on Analyst Estimates Including Price Targets

17 Analysts have issued a LeMaitre Vascular, Inc. forecast:

Buy

59%

Hold

41%

Analyst Estimates with Stock Price Targets

Financial data from LeMaitre Vascular, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	226 226	13% 13% 100%
- Direct Costs	71 71	5% 5% 31%
Gross Profit	156 156	17% 17% 69%
- Selling and Administrative Expenses	81 81	18% 18% 36%
- Research and Development Expense	16 16	9% 9% 7%
EBITDA	59 59	25% 25% 26%
- Depreciation and Amortization	5.73 5.73	5% 5% 3%
EBIT (Operating Income) EBIT	53 53	30% 30% 23%
Net Profit	45 45	33% 33% 20%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

LeMaitre Vascular, Inc. Stock News

Neutral

GlobeNewsWire

●

4 days ago

LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025

BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.

Positive

Seeking Alpha

●

14 days ago

Don't Be Too Cute, Buy These 3 Dividend Growers Instead

We avoid very high-yielding stocks, as the best way to grow richer over time is to own a diversified basket of dividend growth stocks. Today, we're highlighting a leading alternative asset manager, a niche medical devices company, and Michigan's largest regulated utility. Relative to our fair value estimates, the trio of fast-growing businesses are trading at 4% to 7% discounts.

Positive

Seeking Alpha

●

26 days ago

LeMaitre Vascular: Scaling Nicely As Global Demand Builds

LeMaitre's revenue and earnings continue to grow, though profit growth has moderated. The European launch of Artegraft and pending approval of XenoSure in China are key near-term catalysts. The portfolio's increasing share of biologic products combined with operational improvements are supporting high margins.

More LeMaitre Vascular, Inc. News

Company Profile

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Head office	United States
CEO	George LeMaitre
Employees	658
Founded	1983
Website	www.lemaitre.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now